Olaparib + Bevacizumab
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carcinoma, Ovarian Epithelial
Conditions
Carcinoma, Ovarian Epithelial
Trial Timeline
Sep 15, 2023 → Sep 15, 2027
NCT ID
NCT06121401About Olaparib + Bevacizumab
Olaparib + Bevacizumab is a approved stage product being developed by AstraZeneca for Carcinoma, Ovarian Epithelial. The current trial status is active. This product is registered under clinical trial identifier NCT06121401. Target conditions include Carcinoma, Ovarian Epithelial.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06121401 | Approved | Active |
Competing Products
20 competing products in Carcinoma, Ovarian Epithelial